ArticleFrontiers in pharmacology2026
β-Caryophyllene protects against ischemic stroke by inhibiting H3K9 and H3K18 lactylation-mediated cellular pyroptosis.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ischemic stroke is a common and severe cerebrovascular disease with high mortality and disability. Accumulating evidence indicates that β-caryophyllene (BCP) exerts neuroprotective effects against cerebral ischemic injury; however, the precise underlying mechanisms remain largely unexplored. Methods: Focal cerebral ischemia/reperfusion (I/R) mouse models were established Results: We demonstrated that BCP administration significantly reduced cerebral infarct volume, alleviated neurological deficits, and enhanced motor function in mice subjected to transient focal cerebral ischemia. Mechanistically, BCP inhibited pyroptosis and glycolysis in the ischemic penumbra of mice and in BV2 cells following OGD/R. Concomitantly, BCP decreased the levels of H3K9 lactylation (H3K9la) and H3K18 lactylation (H3K18la) in brain tissues of ischemic penumbra and in OGD/R-induced BV2 cells. Notably, co-treatment with lactate attenuated these inhibitory effects and abrogated the neuroprotective efficacy of BCP. Similar results were also obtained in primary microglia. Additionnaly, oxamate (the LDHA inhibitor) simultaneously downregulated the protein levels of H3K9la, H3K18la, and pyroptosis-related factors, while MCC950 (the NLRP3 inflammasome inhibitor) only blocked downstream pyroptosis without affecting histone lactylation. Chip-PCR further demonstrated that OGD/R increased the enrichment of H3K9la and H3K18la at the NLRP3 promoter, which was decreased by BCP and oxamate but not by MCC950. Lactate supplementation partially restored the inhibitory effects of BCP. Conclusion: BCP protects against ischemic stroke by targeting the lactate-histone lactylation-pyroptosis axis, providing a potential therapeutic target for cerebral ischemia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.